Pfizer has agreed to plead guilty to a U.S. criminal charge relating to promotion of Bextra, a pain medicine that is now withdrawn from the market. The company will pay $2.3 billion to settle the allegations that it improperly marketed Bextra and 12 other medicines. According to the U.S. Department of Justice, Pfizer’s marketing team promoted Bextra for acute pain, surgical pain and other unapproved uses, while its salesforce promoted the drug directly to doctors for those unapproved us...